Three world trials leave out of any doubt the spectacular results of antidiabetics known as LPG-1 analogues and Glucosuric or SGLT2 inhibitors.The reduction of mortality due to cardiovascular cause (the most frequent in the new reality of these patients) reaches dimensions that range between 13 percent and 24 percent, an unpublished effect to date.
This has been announced by medical writing the president of the Spanish Society of Internal Medicine (SEMI), Antonio Zapatero, and also his predecessor in office, Emilio Casariego, who have presented, at the meeting of the scientific society in Malaga,to speakers of international projection such as cardiologist David Fitchett, from the Sant Michael de Toronto hospital in Ontorio (Canada).
One of the most renowned broad spectrum studies during the forum, the Leader essay, in effect shows that the liraglutida, an analogous medication of the LPG-1, manages to reduce between 13 and 14 percent the mortality due to cardiovascular cause.
"LPG-1 analogues are drugs that act in homonymous receptors, prevent cardiovascular events and reduce weight in addition to maintaining metabolic control of diabetes, that is, glycosylated hemoglobin values below seven," he saidTo this newspaper Zapatero himself.
The 'RU pack has been published in' The New England '
Another of the trials is the ‘region pack’, which uses packaging, a glycosuric drug, that is, that favors urine elimination from glucose.“In this case, the decrease in cardiovascular mortality with his shot in the patient with diabetes reaches 23 percent, an incredible figure, and is a reference that has been published in the 'Bible' of World Medicine: the American The NewEngland Journal of Medicine, ”said the president of the SEMI.
Finally, the Sustain study, which proves the semaglutida, is revealed as the most notorious of all for its result: up to 24 percent of lower mortality rate attributable to cardiovascular diseases in diabetes patients.The drug belongs to the analogs of the LPG-1, also known as syncretin therapy, which increases insulin production in the pancreas.
Asked about the medicines for usual use in the face of diabetic pathology in Spain, Zapatero recalled that, essentially, they are metformin, which has long been used;DPP4 inhibitors (an enzyme that degrades syncretin hormones);LPG-1 analogues, sulfonylureas (which sometimes cause hypoglycemic complications) and SGLT2 or glucosuric inhibitors.
